<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Current treatment guidelines highlight the importance of aggressive <z:chebi fb="23" ids="18059">lipid</z:chebi>-modifying therapy in reducing cardiovascular risk in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> are established as the cornerstone of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> management in diabetic patients, based on their efficacy in lowering levels of <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>However, <z:chebi fb="0" ids="35664">statins</z:chebi> fail to address the high residual cardiovascular risk in treated patients, some of which may be attributable to <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) and elevated <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and to a preponderance of small, dense <z:chebi fb="15" ids="39026">LDL</z:chebi> particles, indicating the need for further intervention </plain></SENT>
<SENT sid="3" pm="."><plain>Fibrates are effective against <z:hpo ids='HP_0000001'>all</z:hpo> components of atherogenic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical studies, most notably the <z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> Intervention and Event Lowering in <z:mp ids='MP_0002055'>Diabetes</z:mp>, indicate that fibrates, most likely in combination with a <z:chebi fb="0" ids="35664">statin</z:chebi>, have a secondary role in reducing cardiovascular risk in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, particularly in those without prior <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> or patients with low <z:chebi fb="0" ids="47775">HDL-C</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Results are awaited from the ongoing Action to Control Cardiovascular Risk in <z:mp ids='MP_0002055'>Diabetes</z:mp> trial to fully evaluate the outcome benefits of this combination strategy </plain></SENT>
</text></document>